Showing results (111-120 of 148) with videos related to

Sort By:
Pageof 15
Journal of Lipid Research|September 16, 2009
Genetic variation at the NPC1L1 gene locus, plasma lipoproteins, and heart disease risk in the elderlyEliana Polisecki, Inga Peter, Jason S Simon, et al.
JAMA|June 23, 2011
Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysisDavid Preiss, Sreenivasa Rao Kondapally Seshasai, Paul Welsh, et al.
The American Journal of Cardiology|November 27, 2007
Baseline characteristics of participants in the JUPITER trial, a randomized placebo-controlled primary prevention trial of statin therapy among individuals with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive proteinPaul M Ridker, Francisco A H Fonseca, Jacques Genest, et al.
Lancet (London, England)|March 31, 2009
Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trialPaul M Ridker, Eleanor Danielson, Francisco Ah Fonseca, et al.
Circulation. Cardiovascular Quality and Outcomes|December 25, 2009
Number needed to treat with rosuvastatin to prevent first cardiovascular events and death among men and women with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin (JUPITER)Paul M Ridker, Jean G MacFadyen, Francisco A H Fonseca, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|December 25, 2009
Activation of hemostasis and decline in cognitive function in older peopleDavid J Stott, Michele Robertson, Ann Rumley, et al.
The New England Journal of Medicine|November 11, 2008
Rosuvastatin to prevent vascular events in men and women with elevated C-reactive proteinPaul M Ridker, Eleanor Danielson, Francisco A H Fonseca, et al.
The New England Journal of Medicine|March 31, 2009
A randomized trial of rosuvastatin in the prevention of venous thromboembolismRobert J Glynn, Eleanor Danielson, Francisco A H Fonseca, et al.
Atherosclerosis|February 12, 2008
Genetic variation at the LDL receptor and HMG-CoA reductase gene loci, lipid levels, statin response, and cardiovascular disease incidence in PROSPEREliana Polisecki, Hind Muallem, Nobuyo Maeda, et al.
Metabolism: Clinical and Experimental|May 14, 2016
Effects of the BET-inhibitor, RVX-208 on the HDL lipidome and glucose metabolism in individuals with prediabetes: A randomized controlled trialAndrew L Siebel, Si Khiang Trinh, Melissa F Formosa, et al.
Pageof 15